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￿Of importance.
Introduction
A well-recognized cause of secondary hypertension is renal
artery stenosis (RAS), but uncertainty exists regarding
whether it is worthwhile to actively search for this
condition. First, the diagnosis of RAS requires either an
invasive procedure (digital subtraction angiography [DSA])
or a noninvasive yet costly investigation such as magnetic
resonance angiography (MRA) or CT angiography (CTA).
One shared disadvantage of the latter two methods is that it
is necessary to administer contrast material to the patient.
Second, it is not so easy to select for further study those
patients in whom a reasonable chance of finding a stenotic
lesion exists. Finally, an effective treatment must be
available in order to justify screening for RAS. Thus,
starting a diagnostic strategy for RAS in a hypertensive
patient makes sense only if one is prepared to take the
consequences of the outcome and perform angioplasty with
or without stent placement when a stenosis is considered to
be hemodynamically significant. Precisely the last point is
subject to debate. There are few data from randomized trials
on the results of percutaneous transluminal renal angioplas-
ty (PTRA) as compared with medical treatment in hyper-
tensive patients with RAS. These studies were small and
the results were equivocal. With respect to angioplasty plus
stenting, even less information is at hand. Therefore, the
Angioplasty and Stenting for Renal Artery Lesions (AS-
TRAL) trial was designed to explore whether angioplasty
and stenting together with medical treatment would
improve renal function more than medical treatment alone
in patients with atherosclerotic RAS.
Aims
ASTRAL was a multicenter, randomized, unblinded clinical
trial that examined in patients with atherosclerotic RAS
whether revascularization in addition to medical therapy
improves renal function more than medical treatment
alone.
Methods
Over 7 years, the ASTRAL investigators enrolled 806
patients from 57 hospitals (53 in the United Kingdom, 3 in
Australia, and 1 in New Zealand). Patients were eligible
when clinical findings such as treatment resistance or
unexplained renal dysfunction suggested a diagnosis of
atherosclerotic renovascular disease. When DSA, MRA, or
CTA had confirmed the presence of a “substantial” stenosis
in one or more renal arteries, and when the lesion was
P. W. de Leeuw (*)
Department of Medicine, University Hospital Maastricht,
PO Box 5800, 6202 AZ Maastricht, The Netherlands
e-mail: p.deleeuw@intmed.unimaas.nl
Curr Hypertens Rep (2010) 12:143–145
DOI 10.1007/s11906-010-0109-3considered suitable for revascularization, patients were
randomly assigned in a 1:1 ratio to either a group that
underwent revascularization combined with medical treat-
ment or a group receiving medical treatment only. Stratifi-
cation factors during randomization were serum creatinine
concentration, estimated glomerular filtration rate as de-
rived from the Cockcroft-Gault formula [1], severity of
RAS, kidney length on ultrasonography, and rate of
progression of renal impairment in the year preceding
enrollment into the study. Revascularization consisted of
angioplasty, either alone or in combination with stent
placement. Medical therapy was adjusted according to
local protocols but comprised statins, antiplatelet agents,
and antihypertensive drugs. After the procedure, patients
were followed up at 1 to 3 months, 6 to 8 months, and
1 year. Thereafter, they were seen annually for 5 years.
Primary outcome was the change in renal function as
determined from the slope of the reciprocal of serum
creatinine over time. Analysis was by intention-to-treat, and
the study had 80% power to detect a 20% reduction in the
slope. Secondary outcomes were the level of blood
pressure, the time to first renal event, the time to first
major cardiovascular event, and mortality. A substudy
addressed changes in cardiac structure and function, but
results from this analysis are published elsewhere.
Results
The 806 patients were equally divided over both treatment
groups, and there were no significant differences in baseline
characteristics between the two groups. Most patients had
advanced disease with over 70% stenosis or significant renal
impairment. Surprisingly, though, baseline blood pressure
was reasonably well controlled: on average, it was 149/
76 mm Hg in the revascularization group and 152/76 mm Hg
in the medical group. Median follow-up time was 34 months.
A technically successful revascularization was achieved in
317 of the 403 patients who had been assigned to the
intervention group. In 95% of these patients, angioplasty was
accompanied by stent placement. In the medical-therapy
group, a few patients (6%) later underwent revascularization.
Over the 5-year follow-up period, the rate of progression
of renal impairment was slightly less in the revascularization
group, but the difference was small with a confidence
interval crossing zero. No significant between-group differ-
ences in systolic blood pressure were apparent. Rates of renal
events, major cardiovascular events, and death were similar
in the two groups. Revascularization was associated with 31
serious complications in 23 patients. These included two
deaths and three amputations. Post hoc analyses revealed that
the overall results were similar in subgroups with varying
degrees of stenosis or renal function.
Discussion
The authors conclude from their data that revascularization
in patients with atherosclerotic RAS does not produce a
clinically relevant benefit in terms of renal function. The
same is true with respect to the secondary outcome
measures such as blood pressure and renal or cardiovascu-
lar events. On the other hand, the invasive procedure was
associated with substantial risk. The investigators acknowl-
edge that the trial has some limitations, for instance with
respect to the population that they studied. For ethical
reasons, patients were enrolled in the trial only when their
own physician was uncertain as to whether revasculariza-
tion would provide a worthwhile clinical benefit. It is
possible that some patients who did not meet the eligibility
criteria might have benefited from revascularization.
Comments
Although the investigators do not state this explicitly, one
would be inclined to interpret the results of this trial to
show that it is not worthwhile, and even potentially
hazardous, to perform angioplasty with or without stenting
in patients with atherosclerotic RAS. The ASTRAL trial is
not the first to evaluate the effects of revascularization, and
I hope it will not be the last. Three previously reported
randomized trials have compared angioplasty with medical
treatment and have shown virtually no advantage for
angioplasty. Meta-analysis of these three trials showed only
a very modest improvement in blood pressure control [2],
and uncertainty about this issue remained. ASTRAL is the
largest randomized controlled trial so far. Unlike the
previous studies, angioplasty combined with stenting (in
most cases) was the revascularization procedure used in
ASTRAL. In the older trials, angioplasty was not combined
with stent placement. This difference makes a direct
comparison difficult, as angioplasty alone carries a high
risk of stenosis recurrence. Nevertheless, all four trials are
consistent in the sense that the clinical benefit of revascu-
larization is at best marginal.
This is not the end of the story, however. The patients in
ASTRAL and in the other trials all had advanced
atherosclerotic disease. Specifically, patients in ASTRAL
were on average 70 years of age, and most had a stenosis
over 70%. Renal function was markedly impaired, with a
mean serum creatinine level at baseline of 178 μmol/L.
This means that there was already substantial renal damage
and it is a priori highly unlikely that there was much room
for improvement. If we really want to do something for the
kidney or, for that matter, for renovascular disease, we
should probably intervene at an earlier stage, when there is
still viable tissue to be salvaged.
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